Japan-based Chugai Pharmaceutical Co., Ltd. (TSE: 4519) has registered a first-in-human Phase I clinical trial of AQUA07, an oral investigational drug whose mechanism has not been publicly disclosed, in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on at least one prior ALK inhibitor. The AQUA07 clinical trial is notable for its parallel-arm structure: one arm evaluates AQUA07 as monotherapy, while a second tests it in combination with lorlatinib, Pfizer's third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI). The design suggests Chugai may be positioning AQUA07 to address resistance mechanisms that emerge after exposure to later-generation ALK inhibitors — a setting where durable options remain limited.
The Phase I, open-label, multicenter study (NCT07617337) is expected to enroll approximately 102 adults with locally advanced unresectable or metastatic ALK-positive NSCLC, according to the trial record. Patients must have received at least one prior ALK TKI, though those treated exclusively with crizotinib — the first-generation agent — are excluded, effectively enriching the population for individuals who have progressed on second- or third-generation inhibitors such as alectinib, brigatinib, or lorlatinib itself. The study is structured in two parallel dose-escalation parts: Part A evaluates AQUA07 monotherapy, and Part B evaluates AQUA07 in combination with lorlatinib, with each arm seeking to establish the recommended Phase II dose and maximum tolerated dose. Recruitment is anticipated to begin in Q3 2026, with primary completion targeted for August 2030. Secondary endpoints include pharmacokinetic profiling of both AQUA07 and lorlatinib, as well as preliminary efficacy measures — objective response rate, progression-free survival, and duration of response — assessed per RECIST v1.1.
The biological rationale for AQUA07 cannot be fully characterized from available public sources; Chugai has not disclosed the compound's molecular target or mechanism of action ahead of trial initiation, which is consistent with the company's practice for early-stage internal programs. The oral route of administration and classification as a small-molecule drug are confirmed by the trial record, suggesting a kinase inhibitor-type modality, though this remains an inference. The decision to pair AQUA07 with lorlatinib in a dedicated dose-escalation arm — rather than simply evaluating monotherapy activity — implies the compound may act on a pathway distinct from or complementary to direct ALK kinase inhibition, potentially addressing bypass signaling or resistance mutations that limit the durability of ALK TKI monotherapy. Chugai has prior expertise in ALK-positive NSCLC through its development of alectinib (Alecensa), a second-generation ALK inhibitor now widely used as a first-line standard of care.
In the post-lorlatinib resistance setting, the competitive field is sparse but active. The most advanced program is Nuvalent's neladalkib (NVL-655), a brain-penetrant next-generation ALK inhibitor designed to overcome a broad range of resistance mutations, including compound mutations that can emerge following sequential ALK TKI treatment. The agent is currently under US FDA review following positive pivotal data from the ALKOVE program. Chugai's decision to evaluate AQUA07 both as monotherapy and in combination with lorlatinib suggests a potentially differentiated strategy, although the absence of a disclosed molecular target makes direct comparisons premature.